Bradford Shafer Net Worth

The estimated Net Worth of Bradford J Shafer is at least $8.56 Million dollars as of 27 August 2018. Mr. Shafer owns over 7,119 units of Theravance Biopharma Inc stock worth over $680,400 and over the last 10 years he sold TBPH stock worth over $5,412,276. In addition, he makes $2,468,850 as Executive Vice President, General Counsel, and Secretary at Theravance Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Shafer TBPH stock SEC Form 4 insiders trading

Bradford has made over 7 trades of the Theravance Biopharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 7,119 units of TBPH stock worth $197,267 on 27 August 2018.

The largest trade he's ever made was selling 49,122 units of Theravance Biopharma Inc stock on 18 August 2016 worth over $1,348,890. On average, Bradford trades about 4,271 units every 16 days since 2014. As of 27 August 2018 he still owns at least 84,000 units of Theravance Biopharma Inc stock.

You can see the complete history of Mr. Shafer stock trades at the bottom of the page.

Bradford Shafer biography

Bradford J. Shafer Esq., J.D. serves as Executive Vice President, General Counsel, Secretary of the Company. serves as Executive Vice President, General Counsel, Secretary of the Company. He has served as our Executive Vice President, General Counsel since March 2016 and our Secretary since November 2014. Previously, he was our Senior Vice President, General Counsel since September 2014. Prior to joining Theravance Biopharma, Mr. Shafer served as Senior Vice President, General Counsel and Secretary at Innoviva, since August 1999. From 1996 to 1999 he served as General Counsel of Heartport, Inc., a medical device company. From 1993 to 1996, Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor-in-Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude.

What is the salary of Bradford Shafer?

As the Executive Vice President, General Counsel, and Secretary of Theravance Biopharma Inc, the total compensation of Bradford Shafer at Theravance Biopharma Inc is $2,468,850. There are 2 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.

How old is Bradford Shafer?

Bradford Shafer is 59, he's been the Executive Vice President, General Counsel, and Secretary of Theravance Biopharma Inc since 2016. There are 13 older and 14 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

What's Bradford Shafer's mailing address?

Bradford's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Theravance Biopharma Inc

Over the last 10 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.

What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Complete history of Mr. Shafer stock trades at Theravance Biopharma Inc

Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include:

• Rick Winningham,
  Chairman of the Board, Chief Executive Officer
• Andrew Hindman,
  Chief Financial Officer, Senior Vice President
• Bradford Shafer,
  Executive Vice President, General Counsel, Secretary
• Brett Haumann,
  Senior Vice President, Clinical Development and Chief Medical Officer
• Frank Pasqualone,
  Senior Vice President and Chief Commercial Operations Officer
• Philip Worboys,
  Senior Vice President - Research and Translational Science
• Rick E. Winningham M.B.A.,
  Chairman & CEO
• Andrew Asa Hindman,
  Sr. VP & CFO
• Bradford J. Shafer,
  Exec. VP, Gen. Counsel & Sec.
• Andrew Asa Hindman M.B.A,
  Sr. VP & CFO
• Rhonda F. Farnum,
  Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs
• William Young,
  Lead Independent Director
• Burton Malkiel,
  Independent Director
• Donal O'Connor,
  Independent Director
• Dean Mitchell,
  Independent Director
• Susan Molineaux,
  Independent Director
• Eran Broshy,
  Independent Director
• Laurie Alsup,
  Independent Director
• George Whitesides,
  Independent Director
• Robert Gunderson,
  Director
• Deepika Pakianathan,
  Independent Director
• Vijay Sabesan,
  Senior Vice President - Technical Operations
• Kenneth Pitzer,
  Senior Vice President - Product Strategy and Commercial Planning
• Ann Brady,
  President - Theravance Biopharma Ireland Limited
• Dr. Ann B. Brady Ph.D.,
  Pres of Theravance Biopharma Ireland Limited
• Dr. Richard A. Graham Ph.D.,
  Sr. VP of Devel.
• Daniel Long,
  Head of Medicinal Chemistry
• Dr. Kenneth R. Pitzer,
  Sr. VP of Product Strategy & Commercial Planning
• Dr. Phillip D. Worboys,
  Sr. VP of Research & Translational Science
• Dennis O. Driver,
  Sr. VP of HR, Organizational and Leadership Devel.
• Gail B. Cohen,
  VP of Corp. Communications & Investor Relations
• Jeremy T Grant,
  
• Renee D Gala,
  VP-Finance
• Peter S Ringrose,
  Director
• Junning Lee,
  Sr. VP, Technical Operations
• Sharathchandra S Hegde,
  SVP, Research
• Henrietta Fore,
  Director
• Shehnaaz Suliman,
  SVP, Corp Dev & Strategy
• Jeffrey David Jonker,
  Senior VP, Corp. & Bus. Dev.
• Michael G Atieh,
  Director
• Leonard M Blum,
  Sr VP, Chief Comm. Officer
• Inc. Innoviva,,
  10% owner
• Mathai Mammen,
  SVP, Research & Early Clin Dev
• Rhonda Farnum,
  SVP, COMM & MEDICAL AFFAIRS
• Richard A Graham,
  SVP, RESEARCH & DEVELOPMENT
• Plc Gsk,
  
• Aziz Sawaf,
  SVP & CHIEF FINANCIAL OFFICER
• Brett A. Grimaud,
  SVP, GEN COUNSEL AND SECRETARY
• Susannah Gray,
  
• Aine Miller,
  SVP, DEV & HEAD OF IRE OFFICE
• Eli Samaha,
  10% owner